Table A3.
Anthropometric and laboratory parameters of patients.
| Visit | V1 | V2–4 | V5 | V6–8 |
|---|---|---|---|---|
| Days (d) relative to | d −14 | d ‒2 to 0 | d 49 | d 84 to 86 |
| start of supplementation | ||||
| Age (years) | 24 (20–34); range 18–46 | |||
| Choline Intake (days) | – | – | 49 (45–51) | V6: 84 (84–91) |
| Body Weight (kg) | 65 (61–71) | 63 (61–70) | 62 (60–70) | |
| Length (cm) | 173 (171–175) | |||
| BMI (kg/m2) | 22.7 (21.3–23.6) | 21.6 (21.2–23.3) | 21.7 (21.0–23.3) | |
| Heart Rate (bpm) | 72 (72–81) | 77 (73–88) | 78 (72–81) | 78 (73–85) |
| Systolic BP (mmHg) | 120 (112–125) | 117 (73–88) | 115 (114–124) | 114 (110–119) |
| Diastolic BP (mmHg) | 75 (65–75) | 68 (66–76) | 70 (67–76) | 67 (65–73) |
| HbSO2 (%) | 97 (95–97) | 96 (95–97) | 96 (96–97) | 97 (95–98) |
| Sodium (mmol/L) | 141 (139–141) | 141 (140–142) | 140 (137–142) | 140 (139–141) |
| Potassium (mmol/L) | 4.0 (3.9–4.4) | 3.9 (3.7–4.2) | 4.0 (3.9–4.4) | 3.9 (3.7–4.1) |
| Creatinine (mmol/L) | 0.9 (0.7–0.9) | 0.8 (0.7–1.0) | 0.9 (0.7–0.9) | 0.8 (0.7–1.0) |
| Urea (mmol/L) | 33 (26–36) | 27 (25–33) | 31 (26–37) | 29 (23–34) |
| AST (U/L) | 41 (27–74) | 34 (27–50) | 30 (25–41) | 33 (23–37) |
| ALT (U/L) | 48 (27–77) | 35 (27–68) | 36 (27–48) | 34 (27–42) |
| GGT(U/L) | 21 (14–64) | 17 (16–56) | 22 (17–69) | 17 (14–22) |
| AP (U/L) | 116 (103–138) | 125 (102–163) | 97 (95–134) | 117 (105–121) |
| Bilirubin (mg/dL) | 0.70 (0.48–0.95) | 0.65 (0.43–0.90) | 0.60 (0.50–0.70) | 0.75 (0.50–1.08) |
| Cholesterol (mg/dL) | 124 (98–144) | 132 (106–155) | 142 (106–154) | 125 (102–142) |
| HDL-Chol. (mg/dL) | 35 (27–49) | 41 (33–46) | 38 (32–39) | 40 (34–44) |
| LDL-Chol. (mg/dL) | 58 (52–90) | 64 (59–112) | 61 (49–102) | 68 (49–93) |
| Apo-B (mg/dL) | 61 (50–71) | 60 (52–79) | 62 (49–85 | 62 (49–75) |
| Triglycerides (mg/dL) | 65 (62–90) | 64 (56–99) | 84 (65–137) | 87 (64–110) |
| Hemoglobin (g/dL) | 15.5 (15.0–15.9) | 14.7 (14.5–16.4) | 15.0 (14.0–15.2) | 14.7 (14.4–15.6) |
| Leucocytes (µL-1) | 8170 (7103–9413) | 8575 (7033–9610) | 9040 (6840–9580) | 8830 (7265–9890) |
| Thromboc. (x103/mL) | 236 (193–262) | 264 (240–281) | 252 (222–300) | 254 (210–288) |
| CRP (mg/dL) | 0.35 (0.16–0.7) | 0.33 (0.18–0.50) | 0.17 (0.10–0.60) | 0.70 (0.23–0.89) |
| Interleukin 6 (ng/L) | 2.0 (2.0–7.0) | 4.0 (2.5–6.1) | 2.5 (2.0–4.9) | 3.5 (2.5–6.4) |
Data are medians and interquartile range of 10 patients at study entry (visit 1[V1]), start (V2), intermediate visit (V5) and end of supplementation (V6). Abbreviations: ALT, alanine aminotransferase; AP, alkaline phosphatase; Apo-B, apolipoprotein B; AST, aspartate aminotransferase; BP, blood pressure; Chol., cholesterol; CRP, C-reactive protein; GGT, γ-glutamyl transferase; HbSO2, hemoglobin oxygenation; HDL, high-density lipoprotein; LDL, low-density lipoprotein.